Akebia Therapeutics (AKBA) Return on Capital Employed (2017 - 2025)
Historic Return on Capital Employed for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 0.08%.
- Akebia Therapeutics' Return on Capital Employed rose 3200.0% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.34% for FY2024, which is 1000.0% down from last year.
- Akebia Therapeutics' Return on Capital Employed amounted to 0.08% in Q3 2025, which was up 3200.0% from 0.0% recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Return on Capital Employed ranged from a high of 0.08% in Q3 2025 and a low of 0.94% during Q1 2022
- In the last 5 years, Akebia Therapeutics' Return on Capital Employed had a median value of 0.33% in 2023 and averaged 0.41%.
- Per our database at Business Quant, Akebia Therapeutics' Return on Capital Employed plummeted by -3500bps in 2021 and then soared by 7300bps in 2023.
- Quarter analysis of 5 years shows Akebia Therapeutics' Return on Capital Employed stood at 0.87% in 2021, then surged by 66bps to 0.3% in 2022, then decreased by -12bps to 0.33% in 2023, then decreased by -14bps to 0.38% in 2024, then surged by 121bps to 0.08% in 2025.
- Its last three reported values are 0.08% in Q3 2025, 0.0% for Q2 2025, and 0.13% during Q1 2025.